BOIRON And VETOQUINOL Have A High Dividend Yield And Return On Equity In The Drug Manufacturers—Specialty & Generic Industry.

(VIANEWS) – BOIRON (BOI.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Drug Manufacturers—Specialty & Generic industry.

Financial Asset Price Forward Dividend Yield Return on Equity
BOIRON (BOI.PA) €52.90 2.13% 8.13%
VETOQUINOL (VETO.PA) €90.50 0.91% 10.37%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. BOIRON (BOI.PA)

2.13% Forward Dividend Yield and 8.13% Return On Equity

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.

Earnings Per Share

As for profitability, BOIRON has a trailing twelve months EPS of €2.89.

PE Ratio

BOIRON has a trailing twelve months price to earnings ratio of 18.3. Meaning, the purchaser of the share is investing €18.3 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.13%.

Yearly Top and Bottom Value

BOIRON’s stock is valued at €52.90 at 17:40 EST, below its 52-week high of €54.80 and way higher than its 52-week low of €37.00.

Volatility

BOIRON’s last week, last month’s, and last quarter’s current intraday variation average was 0.14%, 0.21%, and 1.47%.

BOIRON’s highest amplitude of average volatility was 0.82% (last week), 1.05% (last month), and 1.47% (last quarter).

Moving Average

BOIRON’s worth is above its 50-day moving average of €49.04 and way above its 200-day moving average of €44.07.

More news about BOIRON.

2. VETOQUINOL (VETO.PA)

0.91% Forward Dividend Yield and 10.37% Return On Equity

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.

Earnings Per Share

As for profitability, VETOQUINOL has a trailing twelve months EPS of €4.06.

PE Ratio

VETOQUINOL has a trailing twelve months price to earnings ratio of 22.29. Meaning, the purchaser of the share is investing €22.29 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.37%.

More news about VETOQUINOL.

Leave a Reply

Your email address will not be published. Required fields are marked *